Erytech Pharma (NASDAQ:ERYP) and Microbot Medical (NASDAQ:MBOT) Critical Analysis
Microbot Medical (NASDAQ:MBOT) and Erytech Pharma (NASDAQ:ERYP) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability and earnings.
This is a summary of current ratings and recommmendations for Microbot Medical and Erytech Pharma, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
This table compares Microbot Medical and Erytech Pharma’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings & Valuation
This table compares Microbot Medical and Erytech Pharma’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Microbot Medical||N/A||N/A||-$7.25 million||N/A||N/A|
|Erytech Pharma||N/A||N/A||-$70.18 million||($3.92)||-2.15|
Risk & Volatility
Microbot Medical has a beta of 4.35, suggesting that its share price is 335% more volatile than the S&P 500. Comparatively, Erytech Pharma has a beta of 2.54, suggesting that its share price is 154% more volatile than the S&P 500.
Institutional & Insider Ownership
10.7% of Microbot Medical shares are held by institutional investors. Comparatively, 7.4% of Erytech Pharma shares are held by institutional investors. 14.5% of Microbot Medical shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Microbot Medical beats Erytech Pharma on 5 of the 8 factors compared between the two stocks.
About Microbot Medical
Microbot Medical Inc., a pre-clinical medical device company, researches, designs, and develops micro-robotics assisted medical technologies targeting the minimally invasive surgery space. The company, through its ViRob and TipCAT micro-robotic technologies, is developing two product candidates, including the Self Cleaning Shunt for the treatment of hydrocephalus and normal pressure hydrocephalus; and a self-propelling, semi-disposable endoscope, which is used in colonoscopy procedures. It also holds an intellectual property portfolio that comprises 9 patent families, which include 9 patents granted in the United States, 12 patents granted outside the United States, and 15 patent applications pending worldwide. Microbot Medical Inc. was founded in 2010 and is based in Hingham, Massachusetts.
About Erytech Pharma
ERYTECH Pharma S.A., a biopharmaceutical company, develops therapies for severe forms of cancer and orphan diseases. It is developing a pipeline of product candidates targeting solid and liquid tumors for patients with high unmet medical needs. The company's lead product candidate is eryaspase, which is used for the treatment of severe solid tumors, including pancreatic cancer and in acute lymphoblastic leukemia. It is preparing for the launch of a pivotal Phase III clinical trial of eryaspase in the United States and Europe. ERYTECH Pharma S.A. has research collaborations with the Fox Chase Cancer Center to advance the preclinical development of erymethionase for the treatment of homocystinuria and with Queen's University of Canada to advance the preclinical development of eryminase for the treatment of arginase-1-deficiency. ERYTECH Pharma S.A. was founded in 2004 and is based in Lyon, France.
Receive News & Ratings for Microbot Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Microbot Medical and related companies with MarketBeat.com's FREE daily email newsletter.